On Monday, Geron Corporation (NASDAQ:GERN)’s shares surged 3.43% to $4.22, as a clinical stage biopharmaceutical company, declared that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the company at the 14th Annual Needham Healthcare Conference in New York. The presentation is planned to occur on Tuesday, April 14, at 5:00 p.m. Eastern Time.
Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has partnershipand license contract with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, counting hematologic myeloid malignancies and other human therapeutic uses.
Exelixis, Inc. (NASDAQ:EXEL)’s shares gained 3.29% to $3.14, during the last trading session on Monday, after a biopharmaceutical company, declared that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to cabozantinib for treatment of patients with advanced renal cell carcinoma (RCC) who have received one preceding therapy. Cabozantinib is the company’s lead compound and inhibits the activity of multiple tyrosine kinases counting MET, VEGFRs and RET. The FDA created the Fast Track process to facilitate the development and expedite the review of drugs to treat serious diseases and address unmet medical needs. Fast Track designation confers important benefits, counting the potential eligibility for Priority Review of a New Drug Application, if relevant criteria are met.
Cabozantinib is the subject of METEOR, an ongoing phase 3 pivotal trial in patients with metastatic RCC who have practiced disease progression following treatment with at least one VEGFR tyrosine kinase inhibitor. Patients are randomized 1:1 to receive 60 mg of cabozantinib daily or 10 mg of everolimus daily. The primary endpoint of METEOR is progression-free survival, and secondary endpoints comprise overall survival and objective response rate. Exelixis anticipates to release top-line results from the trial in the second quarter of 2015. In addition to the metastatic RCC development program, Exelixis is also evaluating cabozantinib in CELESTIAL, a phase 3 pivotal trial in second-line hepatocellular carcinoma (HCC).
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
At the end of Monday’s trade, Blackstone Mortgage Trust, Inc. (NYSE:BXMT)’s shares gained 3.08% to $31.11, hitting its highest level, after a real estate finance company, declared it will file a Form 8-K with the Securities and Exchange Commission with information regardingits projected attainment of a portfolio of commercial loans from GE Capital Real Estate, preliminary results for the quarter ended March 31, 2015 and certain other matters.
Due to systems delays regarding submission of SEC filings, the Form 8-K and a preliminary prospectus supplement referred to in the Form 8-K can be viewed at www.bxmt.com in the interim.
Blackstone Mortgage Trust, Inc., a real estate finance company, originates and purchases senior loans collateralized by properties in North America and Europe. It operates through two segments, Loan Origination and CT Legacy Portfolio. The company qualifies as a real estate investment trust for federal revenue tax purposes. It generally would not be subject to U.S. federal revenue taxes if it distributes at least 90% of its taxable revenue to its stockholders.
Finally, Memorial Resource Development Corp. (NASDAQ:MRD), ended its Monday’s trading session with 3.01% gain, and closed at $18.14, as Global Hunter Securities Initiated its coverage on Memorial Resource with “Buy” rating, on April 8.
Memorial Resource Development Corp., an independent natural gas and oil company, focuses on the attainment, exploitation, and development of natural gas, natural gas liquids, and oil properties primarily in North Louisiana.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
